U.S. health experts this week will decide whether to recommend approval for Biogen Inc.’s experimental Alzheimer’s drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if the antibody aducanumab works.
A new study suggests that some patients could see a decline in cognition that is equivalent to the brain aging approximately 10 years.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).
A study of more than a thousand former professional soccer players has uncovered significantly more deaths from brain disease than among non-players.
Hearing loss in middle age is associated with higher odds of cognitive decline and dementia in later years, suggests a large study in Taiwan.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
Shares of Eisai Co. Ltd. plunged as much as 21 percent after the results of the company’s experimental Alzheimer’s drug being developed with partner Biogen Inc. failed to enthuse investors.
For soccer players, regularly “heading” the ball may have a bigger effect on everyday cognitive functioning than occasional accidental head impacts, a U.S. study suggests.
Hearing impairment is already linked to a heightened risk of cognitive decline in old age, and a new study suggests that impaired vision may carry the same risk.